Skip to main content

Table 2 Univariate analysis by chi-square test or Fisher’s exact test

From: Nephrotoxicity of cisplatin combination chemotherapy in thoracic malignancy patients with CKD risk factors

Risk factor Odds ratio 95 % C.I. P-value
CKD risk factors    
 Smoking 0.7 0.19–2.53 0.59
 Hypertension 2.3 0.79–6.66 0.12
 Dyslipidemia 2.25 0.70–7.20 0.17
 Use of NSAIDs 3.56 1.11–11.39 0.04
 Obesity 0.51 0.10–2.50 0.4
 Diabetes mellitus 0.91 0.17–4.70 0.91
 Hyperuricemia 1.05 0.20–5.57 0.95
 Urinary tract stone -   0.12
 Age ≥70 0.5 0.06–4.31 0.52
 Cardiac disease 6 1.21–29.87 0.04
 Hematuria -   0.29
 Cerebrovascular disease -   0.29
 Autoimmune disease 4 0.52–30.61 0.15
 Proteinuria -   0.6
 Infectious disease -   -
 Past history of ARF -   -
 Pt. with CKD risk -   0.29
 Pt. without CKD risk -   0.29
No. of CKD risk factors    
 ≤2 1   
 3 1.54 0.39–5.96 0.72
 4 1.5 0.34–6.7 0.69
 ≥5 5 0.85–29.39 0.09
Other risk factors    
 PS ≥1 0.68 0.23–2.01 0.48
 Alb <3.5 g/dL 0.69 0.24–1.97 0.49
 Female 1.43 0.44–4.69 0.56
Anticancer drugs    
 Vinorelbine 1 0.35–3.25 0.9
 Etoposide 2.44 0.70–8.49 0.15
 Docetaxel 0.7 0.14–3.53 0.66
 Pemetrexed 0.33 0.04–2.76 0.29
 Gemcitabine 3.94 0.51–30.14 0.16
 S-1 3.94 0.51–30.14 0.16
  1. AKI acute kidney injury, CKD chronic kidney disease, NSAID non-steroidal anti-inflammatory drug, ARF acute renal failure, PS performance status, C.I. confidential interval
  2. Bold P-values are significant at the 0.05 level